Memantina Aurovitas

Memantine, the active ingredient in Memantina Aurovitas, is an NMDA receptor antagonist presented as an oral tablet for oral use. It treats moderate to severe Alzheimer’s disease in adult patients by helping to preserve cognitive function and daily activities.

GNH USA supplies Memantina Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent product availability and regulatory support across multiple regions.

Memantina Aurovitas (memantine) is employed in the therapeutic approach to neurodegenerative disorders, specifically targeting the glutamatergic excitotoxic pathway implicated in Alzheimer’s disease. By modulating NMDA receptor activity, it helps to stabilize neuronal function and mitigate progressive cognitive decline. Alzheimer's disease (moderate to severe): Improves cognition, functional abilities, and overall daily performance in affected patients.

Memantina Aurovitas may be associated with a range of adverse reactions, varying from mild to severe. Common Side Effects: - Dizziness - Headache - Constipation Serious or Rare Side Effects: - Seizures - Severe allergic reactions (e.g., rash, angioedema) - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When prescribing Memantina Aurovitas, clinicians should consider several safety factors. - Renal impairment: Adjust dose or monitor renal function closely. - Hepatic impairment: Use with caution; monitor liver enzymes. - History of seizures: Evaluate risk; may increase seizure frequency. - Cardiovascular disease: Monitor blood pressure and heart rate regularly. - Concomitant NMDA antagonists: Avoid combined use to prevent additive neuro‑inhibition. - Store at room temperature: Keep in original container, protect from moisture and direct sunlight.

Memantina Aurovitas can interact with other medicines, requiring attention to potential effects. Major Interactions (Avoid): - Other NMDA antagonists (e.g., amantadine, dextromethorphan): May cause excessive inhibition. - Strong CYP450 inducers (e.g., carbamazepine, phenytoin): Reduce memantine plasma levels. - Drugs that lower seizure threshold (e.g., bupropion): Increase risk of seizures. Moderate Interactions (Monitor Closely): - Antihypertensive agents: Memantine may enhance hypotensive effect. - Anticholinergic medications: May blunt cognitive benefits. - Selective serotonin reuptake inhibitors (SSRIs): Potential for increased serotonergic activity.